Uday Mukherjee, MD
Psychiatry · Walnut Creek, CANPI 1659457075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$944
- Alkermes, Inc.$814
- Neurocrine Biosciences, Inc.$736
- Teva Pharmaceuticals USA, Inc.$693
- plus $4K from 16 others
What the payments were for
- Food & beverage$10,143100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 80 | $2,094 |
| Otsuka America Pharmaceutical, Inc. | 41 | $1,251 |
| AbbVie(2 entities) | 61 | $944 |
| Alkermes, Inc. | 38 | $814 |
| Neurocrine Biosciences, Inc. | 25 | $736 |
| Teva Pharmaceuticals USA, Inc. | 20 | $693 |
| Supernus Pharmaceuticals, Inc. | 5 | $662 |
| Johnson & Johnson | 13 | $541 |
| Lundbeck LLC | 22 | $446 |
| E.r. Squibb & Sons, L.L.C. | 14 | $341 |
| Axsome Therapeutics, Inc. | 8 | $315 |
| Bausch Health US, LLC | 15 | $263 |
| Almatica Pharma LLC | 8 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $232 |
| Vanda Pharmaceuticals Inc. | 7 | $202 |
| Indivior Inc. | 5 | $131 |
| Collegium Pharmaceutical, Inc. | 3 | $71 |
| Tris Pharma Inc | 4 | $63 |
| Ironshore Pharmaceuticals Inc. | 2 | $48 |
| Corium, LLC | 2 | $48 |
| Biogen | 1 | $30 |
| Adlon Therapeutics L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$577
- REXULTI$363
- CAPLYTA$249
- INVEGA SUSTENNA$128
- INVEGA TRINZA$128
- AUSTEDO$125
- INGREZZA$124
- SPRAVATO$124
- VRAYLAR$123
- Auvelity$106
How this compares
$10,187 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 12 | $20,191 |
| BelsomraSuvorexant | 13 | $5,193 |
| Lurasidone Hcl | 17 | $4,889 |
| Mirtazapine | 141 | $1,868 |
| Aripiprazole | 61 | $1,836 |
| Duloxetine Hcl | 82 | $1,631 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 15 | $1,467 |
| Bupropion XlBupropion Hcl | 77 | $1,463 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 77 | $1,361 |
| Gabapentin | 155 | $1,197 |
| Escitalopram Oxalate | 137 | $1,105 |
| Bupropion Hcl SrBupropion Hcl | 92 | $1,021 |
| Vilazodone Hcl | 15 | $1,013 |
| Buspirone Hcl | 86 | $971 |
| Ziprasidone Hcl | 24 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,094 | $20,19112 claims |
| Almatica Pharma LLCSertraline Hcl | $248 | $86175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Walnut Creek
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.